# **Digestive Enzymes**

Source: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=enzyme.multi(=eng

Extracted: 2025-08-26T06:37:25.731961

Digestive Enzymes Help on accessing alternative formats, such as Portable Document Format ( PDF ), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section. (PDF Version - 85 KB) This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes Any ingredient in Table 1 may be formulated as single ingredient products, or two or more ingredients may be combined to form multi-ingredient products. In addition, multi- ingredient products may be formulated from one or more ingredients from these tables with ingredients from any one or more of the following single ingredient monographs: Alpha-amylase, alpha-galactosidase, Cellulase, Chymotrypsin, Fruit bromelain, Fungal protease, Lactase, Lipase, Pancreatic enzymes, Papain, Stem bromelain and/or Trypsin. The International Union of Biochemistry and Molecular Biology (IUBMB) enzyme nomenclature identification number (IUBMB No.) is not required on the PLA form but may be provided as additional information. Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion. The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant. Date June 3, 2019 Proper name(s), Common name(s), Source material(s) Table 1. Proper name(s), Common name(s), Source material(s) Proper name(s) Common name(s) Source material(s) Proper name(s) Part(s) Group 1: Carbohydrases 1,3-(1-3,1-4)-beta-D-glucan 3(4)-glucanohydrolase beta-1,3-glucanase beta-Glucanase Aspergillus niger Trichoderma longibrachiatum Trichoderma reesei Whole 1,4-alpha-D-Glucan glucohydrolase 4-alpha-D-Glucan glucohydrolase Acid maltase Amyloglucosidase Glucoamylase Aspergillus niger Aspergillus oryzae Rhizopus niveus Rhizopus oryzae Whole 1,3-beta-D-xylan xylanohydrolase 1,4-beta-D-mannan mannanohydrolase 1,5-alpha-L-arabinan arabinanohydrolase alpha-L-arabinofuranoside arabinofuranohydrolase Hemicellulase Aspergillus niger Aspergillus oryzae Trichoderma longibrachiatum Trichoderma beta-D-fructofuranoside fructohydrolase beta-Fructofuranosidase Invertase Sucrase Aspergillus niger Saccharomyces cerevisiae Whole 4-alpha-D-Glucan glucanohydrolase 1,4-alpha-D-glucan glucanohydrolase alpha-Amylase Diastase Fungal diastase Taka-Diastase (Aspergillus) Aspergillus niger Aspergillus oryzae Whole Malt diastase Maltase Malt diastase Hordeum vulgare Seed (1-4)-alpha-D-galacturonan glycanohydrolase Pectin pectylhydrolase Poly(1,4-alpha-D-galacturonide) glycanohydrolase Poly(1,4-alpha-D-galacturonide) lyase Poly(methoxyl-L-galacturonide) lyase Pectinase Polygalacturonase Aspergillus niger Aspergillus oryzae Trichoderma longibrachiatum Trichoderma reesei Whole 1,3-beta-D-xylan xylanohydrolase 1,4-beta-D-xylan xylanohydrolase beta-1,3-xylanase beta-1,4-xylanase Xylanase Trichoderma longibrachiatum Trichoderma reesei Whole Group 2: Proteases Proper name(s) Common name(s) Source material(s) Proper name(s) Part(s) Bacterial Protease Bacterial Protease Neutral protease Bacillus subtilis Whole Pepsin A Pepsin B Pepsin Sus scrofa Stomach Group 3: Other enzymes Proper name(s) Common name(s) Source material(s) Proper name(s) Part(s) Hydrogen-peroxide: hydrogen-peroxide oxidoreductase Aspergillus niaer Saccharomyces cerevisiae Whole myo-Inositol-hexakisphosphate 3-phosphohydrolase myo-Inositol-hexakisphosphate 4-phosphohydrolase orthophosphoric-mono phosphohydrolase 1-Phytase 3-Phytase 4-Phytase 6-Phytase Phytase Aspergillus niger Whole References: Proper names: IUPAC-IUBMB 2012; Common names: IUPAC-IUBMB 2012; Source materials: FCC 8 2012, Justice Canada 2012, Enzyme Technical Association (no date). Route of Administration Oral Dosage Form(s) This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document. Acceptable dosage forms for any age category listed in this monograph for the specified route of administration are listed in the Compendium of Monographs Guidance Document. Use(s) or Purpose(s) Digestive enzyme(s) Dose(s) Subpopulation(s) Adults 18 years and older Quantity(ies) Table 2. Daily maximum of enzymatic activity unit Medicinal ingredients Daily maximum (enzymatic activity unit/day) Bacterial protease Not to exceed 490,000 FCC PC Beta-glucanase Not to exceed 210 FCC BGU Catalase Not to exceed 3,200 FCC Baker Diastase Not to exceed 6,000 FCC DP Glucoamylase (Amyloglucosidase) Not to exceed 300 FCC AGU 1 Hemicellulase Not to exceed 45,000 FCC HCU Invertase Not to exceed 3,000 FCC INVU or Not to exceed 4,200 FCC SU Malt diastase Not to exceed 6,000 FCC DP Pectinase Not to exceed 180 Endo-PG

Pepsin Not to exceed 1,900,000 FCC Pepsin Phytase Not to exceed 75 FCC FTU Xylanase Not to exceed 3,300 XU 1 For the FCC Glucoamylase Activity (Amylogucosidase Activity) assay, the Abbreviation "FCC AGU" is acceptable. Notes The Quantity per dosage unit must be the enzymatic activity (FCC unit). The quantity of the enzymatic preparation in mg or ml should also be included as additional quantity. Direction(s) for use Take with food/meal. Duration(s) of Use Consult a health care practitioner/health care provider/health care professional/doctor/physician for prolonged use. Risk Information Caution(s) and warning(s) For all medicinal ingredients and ingredient combinations Consult a health care practitioner/health care provider/ health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. For products containing one or health care practitioner/health carbohydrases Consult а care professional/doctor/physician prior to use if you have diabetes. For products containing one or more proteases Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have gastrointestinal lesions/ulcers or are having surgery. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking blood thinners or anti-inflammatory agents. Contraindication(s) No statement required. Known adverse reaction(s) For all medicinal ingredients and ingredient combinations Stop use if hypersensitivity/allergy occurs. Non-medicinal ingredients Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database. Storage conditions No statement is required. Specifications The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide. The medicinal ingredient must comply with the requirements outlined in the NHPID. Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient. The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the current Food Chemicals Codex (FCC): beta-GLUCANASE ACTIVITY GLUCOAMYLASE ACTIVITY (AMYLOGLUCOSIDASE ACTIVITY) HEMICELLULASE ACTIVITY INVERTASE SUMNER UNIT ACTIVITY DIASTASE ACTIVITY PROTEOLYTIC ACTIVITY, BACTERIAL (PC) PEPSIN ACTIVITY CATALASE ACTIVITY PHYTASE ACTIVITY Testing for enzymatic activity of the medicinal ingredient must be done at the appropriate stages of formulation and manufacturing using the assay outlined in the Food Chemicals Codex (FCC 5): INVERTASE ACTIVITY Testing for Endo-Polygalacturonase Activity must be done at the appropriate stages of formulation and manufacturing as outlined in Blandino et al. (2002). Testing for Xylanase Activity must be done at the appropriate stages of formulation and manufacturing as outlined in Ghose and Bisaria (1987). Manufacturers are responsible for ensuring that activity assays that are used outside the conditions specified in the FCC have been sufficiently validated for their intended use in accordance with the requirements of good manufacturing practices. Where published assays are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label. References Cited Blandino A, Igbalsyah T, Pandiella SS, Cantero D, Webb C. Polygalacturonase production by Aspergillus awamori on wheat in solid-state fermentation. Applied Microbiology and Technology 2002;58:164-169. Ghose TK, Bisaria VS. Measurement of hemicellulase activities part 1: Xylanases. Pure and Applied Chemistry 1987;59(12):1739-1752. ETA: Enzyme Technical Association. Enzyme Preparations used in Food Processing (as compiled by the ETA members). [Internet] [Accessed 2019 May 21]. https://www.enzymetechnicalassociation.org/enzymes/food/ FCC 8: Food Chemicals Codex. Eighth edition. Rockville (MD): The United States Pharmacopeial Convention; 2012. FCC 5: Food Chemical Codex. Fifth edition. Washington (DC): The National Academy of Sciences; 2001. IUBMB 2012: International Union of Pure and Applied Chemistry and International Union of Biochemistry (IUPAC) and Molecular Biology (IUBMB). IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (JCBN) [Internet]. [Accessed 2019 May 21]. Available from: https://www.gmul.ac.uk/sbcs/iubmb/nomenclature/ Justice Canada. Food and Drug Regulations (C.R.C., c. 870); B.16.100; Table 5. [Internet]. Ottawa (ON): Justice Canada. [Accessed 2019 May 21]. Available from: https://laws.justice.gc.ca/eng/regulations/c.r.c.,\_c.\_870/index.html References Reviewed United States Food and Drug Administration. GRAS Notice Inventory. [Internet]. [Accessed 2012 March 21]. Available http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASL istings/default.htm EFSA Panel on Biological Hazards. Scientific Opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed (2009 update). EFSA Journal 2009;7(12):1431. Report a problem on this page Date modified: 2019-03-01

### **DOSAGE FORM(S)**

Acceptable dosage forms for any age category listed in this monograph for the specified route of administration are listed in the Compendium of Monographs Guidance Document.

#### **RISK INFORMATION**

Caution(s) and warning(s) For all medicinal ingredients and ingredient combinations Consult a health care practitioner/health care provider/ health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. For products containing one or more carbohydrases Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have diabetes. For products containing one or more proteases Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have gastrointestinal lesions/ulcers or are having surgery. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking blood thinners or anti-inflammatory agents. Contraindication(s) No statement required. Known adverse reaction(s) For all medicinal ingredients and ingredient combinations Stop use if hypersensitivity/allergy occurs.

#### NON-MEDICINAL INGREDIENTS

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database. Storage conditions No statement is required.

## STORAGE CONDITION(S)

No statement is required.

#### **SPECIFICATIONS**

The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide. The medicinal ingredient must comply with the requirements outlined in the NHPID. Details of the manufacturing of the enzyme at the raw material stage should include fermentation medium and the isolation process of the medicinal ingredient. The specifications must include testing for enzymatic activity of the medicinal ingredient at appropriate stages of formulation and manufacturing using the assay outlined in the Food Chemicals Codex (FCC):beta-GLUCANASE ACTIVITYGLUCOAMYLASE (AMYLOGLUCOSIDASE **ACTIVITY)HEMICELLULASE ACTIVITYINVERTASE SUMNER** ACTIVITYDIASTASE ACTIVITYPROTEOLYTIC ACTIVITY, BACTERIAL (PC)PEPSIN ACTIVITYCATALASE ACTIVITYPHYTASE ACTIVITYTesting for enzymatic activity of the medicinal ingredient must be done at the appropriate stages of formulation and manufacturing using the assay outlined in the Food Chemicals Codex (FCC 5): INVERTASE ACTIVITYTesting for Endo-Polygalacturonase Activity must be done at the appropriate stages of formulation and manufacturing as outlined in Blandino et al. (2002). Testing for Xylanase Activity must be done at the appropriate stages of formulation and manufacturing as outlined in Ghose and Bisaria (1987). Manufacturers are responsible for ensuring that activity assays that are used outside the conditions specified in the FCC have been sufficiently validated for their intended use in accordance with the requirements of good manufacturing practices. Where published assays are not suitable for use, manufacturers will use due diligence to ensure that the enzymes remain active to the end of the shelf life indicated on the product label.

#### **REFERENCES**

Route of Administration Oral

Proper name(s)	Common name(s)	Source material(s)	
Proper name(s)	Part(s)		
Group 1: Carbohydrases			
1,3-(1-3,1-4)-beta-D-glucan 3(4)-glucanohy	rblatae1,3-glucanasebeta-Glucanase	Aspergillus nigerTrichoderma longibrachiatu	m <b>V⊽riohe</b> oderm
1,4-alpha-D-Glucan glucohydrolase4-alpha-	DA <b>GidoraalgiseAlnydoojass</b> osidaseGlucoamylas	eAspergillus nigerAspergillus oryzaeRhizopu	s Millhæolles Rhizo
1,3-beta-D-xylan xylanohydrolase1,4-beta-E	- <b>Hamiællmase</b> anohydrolase1,5-alpha-L-ara	pi Aspengibusanigley Aspesejillusharlyzana Triiobfode	nto de ingentation
beta-D-fructofuranoside fructohydrolasebeta	-FiruettalseSuosialase	Aspergillus nigerSaccharomyces cerevisiae	Whole
4-alpha-D-Glucan glucanohydrolase	1,4-alpha-D-glucan glucanohydrolasealpha-	A <b>AsphaseiDiusstaigerAspperbillastaspezEus</b> ka-Diasta	skeV <b>(∧oske</b> pergilu
Malt diastase	MaltaseMalt diastase	Hordeum vulgare	Seed
(1-4)-alpha-D-galacturonan glycanohydrola	e <b>PectiinaseRollyydrataseRaly(</b> 1,4-alpha-D-gal	a Asponigilla) sglyigam Asperglase Polyz(a e Tradploak	Dr <b>hitjárladat</b> gitonaic
1,3-beta-D-xylan xylanohydrolase1,4-beta-[	-kwydtam 1x, Øl-avykdmyadselaasta-1,4-xylanaseXylanas	eTrichoderma longibrachiatumTrichoderma r	ee\&align* in the control of th
Group 2: Proteases			
Proper name(s)	Common name(s)	Source material(s)	
Proper name(s)	Part(s)		
Bacterial Protease	Bacterial ProteaseNeutral protease	Bacillus subtilis	Whole
Pepsin APepsin B	Pepsin	Sus scrofa	Stomach
Group 3: Other enzymes			
Proper name(s)	Common name(s)	Source material(s)	
Proper name(s)	Part(s)		
Hydrogen-peroxide: hydrogen-peroxide oxid	o Candatase	Aspergillus nigerSaccharomyces cerevisiae	Whole
myo-Inositol-hexakisphosphate 3-phosphoh	ydr@laştansç8-Pilogitaslel4eRalyitspite@sPhatesePh	ប <b>ង្កាន់ច្រុះស្វៀវ បា</b> ង <b>ទ</b> េញមាវ hophosphoric-mono ester p	h <b>láspále</b> hydro

Medicinal ingredients	Daily maximum (enzymatic activity u
Bacterial protease	Not to exceed 490,000 FCC PC
Beta-glucanase	Not to exceed 210 FCC BGU
Catalase	Not to exceed 3,200 FCC Baker
Diastase	Not to exceed 6,000 FCC DP

Glucoamylase (Amyloglucosidase)	Not to exceed 300 FCC AGU1	
Hemicellulase	Not to exceed 45,000 FCC HCU	
Invertase	Not to exceed 3,000 FCC INVUorNot to exc	eed 4,200 FCC SU
Malt diastase	Not to exceed 6,000 FCC DP	
Pectinase	Not to exceed 180 Endo-PG	
Pepsin	Not to exceed 1,900,000 FCC Pepsin	
Phytase	Not to exceed 75 FCC FTU	
Xylanase	Not to exceed 3,300 XU	